Idarucizumab (Praxbind(®)) for dabigatran reversal in patients undergoing heart transplantation: a cohort of ten patients

BACKGROUND: Novel oral anticoagulants are used in atrial fibrillation. Idarucizumab has been approved for reversal of dabigatran in situations of life-threatening hemorrhage or emergency surgery. OBJECTIVES: We report a single center experience of ten patients on dabigatran therapy who were given id...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Future Sci OA
Main Authors: Kalmanovich, Eran, Battistella, Pascal, Rouviere, Philippe, Albat, Bernard, Frapier, Jean-Marc, Demaria, Roland, Huet, Fabien, Agullo, Audrey, Mourad, Marc, Colson, Pascal, Leclercq, Florence, Gaudard, Philippe, Roubille, François
Formato: Artigo
Idioma:Inglês
Publicado: Future Science Ltd 2021
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8015660/
https://ncbi.nlm.nih.gov/pubmed/33815827
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2144/fsoa-2020-0186
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares